Raptor Pharmaceuticals Provides Update of Produc...( Poster at Upcoming Internat...),Health

Poster at Upcoming International Liver Cancer Conference

Status of Ongoing Programs

Regulatory Consulting Firm Retained

NOVATO, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP.OB) announced today that Dr. Todd Zankel, the Company's Chief Scientific Officer, will present a poster detailing promising preclinical results from two preclinical studies of its HepTide(TM) liver targeting program at the International Liver Cancer ("ILCA") Conference, to be held October 5-7, 2007 in Barcelona, Spain.

Dr. Zankel's presentation will include an update on Raptor's liver targeting platform based on human receptor-associated protein ("RAP"). For more information on ILCA and the 2007 ILCA Conference, please visit http://www.ilca-online.org. A synopsis of the poster will be available in the investor relations section of Raptor's website at http://www.raptorpharma.com shortly after Dr. Zankel presents at the conference.

Current Program Updates:

Investigational New Drug Application ("IND")-Enabling Studies Initiated for HepTide(TM)

Based on promising results from ongoing preclinical studies of its RAP liver targeting program, Raptor has initiated a pre-IND program for HepTide(TM) (its liver targeting therapeutic conjugate using the RAP targeting platform). The Company's goal is to file an IND for this therapeutic conjugate with the Food and Drug Administration (the "FDA") by the end of the second calendar quarter of 2008. To help execute this plan the Company has retained Regulatory Professionals, Inc., a regulatory consulting firm experienced in working with the FDA in all aspects of regulatory affairs including preclinical and clinical support for pre- and post-approval products, and preparation and submis
'/>"/>